Olympus Biotech puts a fork into its efforts to commercialize OP-1

OLYMPUS HALTS OP-1 EFFORT (Orthopedics This Week) Olympus Biotech Corporation has put a fork into its efforts to commercialize OP-1. After paying $60 million to Stryker Corporation in 2010 for the biologic product that has snake-bitten everyone who has attempted to commercialize the protein, Olympus announced on June 18, 2014 that it will close its 120-employee manufacturing plant in West Lebanon, New Hampshire, because it has been unable to find a buyer for the past four months. OP-1 was a disaster for Stryker as the company failed to get FDA approval for the product, paid millions in fines f...


Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !
 

Scroll to Top